Drug Healthc Patient Saf. 2013;5:37-47. doi: 10.2147/DHPS.S28822. Epub 2013 Feb 26.

Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits.

Drug, healthcare and patient safety

Jan Thöne, Gisa Ellrichmann

PMID: 23459383 PMCID: PMC3585507 DOI: 10.2147/DHPS.S28822

Abstract

Multiple sclerosis (MS) is a chronic immunological disease of the central nervous system characterized by early inflammatory demyelination and subsequent neurodegeneration. Major therapeutic progress has occurred during the past decade, in particular since the introduction of immunomodulatory agents, however, MS is still an incurable disease. In addition, parenteral application of the currently licensed drugs is associated with injection-related adverse events (AEs) and low patient compliance. Thus, there remains an unmet need for the development of more effective and well tolerated oral therapies for the treatment of MS. A number of new orally administered agents including fingolimod, laquinimod, teriflunomide, cladribine, and BG-12 have been licensed recently or are currently under investigation in relapsing remitting MS patients. In multi-center, randomized, placebo-controlled phase III clinical studies, all of these agents have already shown their efficacy on both clinical disease parameters and magnetic resonance imaging-based measures of disease activity in patients with relapsing remitting MS. However, there are essential differences concerning their clinical efficacy and side-effect profiles. Additionally, the mechanisms by which these substances exert clinical efficacy have not been fully elucidated. In this article, we review the pharmaceutical properties of fingolimod, laquinimod, teriflunomide, cladribine, and BG-12; and their suggested mechanisms of action, clinical efficacy, and side-effect profiles.

Keywords: cladribine; fingolimod (FTY); fumaric acid esters (BG-12); laquinimod; teriflunomide

References

1. Expert Opin Drug Metab Toxicol. 2011 Mar;7(3):365-70 - PubMed
2. J Neurol. 2010 Feb;257(2):163-70 - PubMed
3. Mult Scler. 2010 Nov;16(11):1360-6 - PubMed
4. Lancet Neurol. 2012 May;11(5):420-8 - PubMed
5. J Neuroimmunol. 2006 Apr;173(1-2):69-78 - PubMed
6. Lancet. 2008 Oct 25;372(9648):1502-17 - PubMed
7. Lancet. 2008 Jun 21;371(9630):2085-92 - PubMed
8. CNS Drugs. 2011 Aug;25(8):673-98 - PubMed
9. Eur J Neurol. 2006 Jun;13(6):604-10 - PubMed
10. Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1716-20 - PubMed
11. Am J Pathol. 2012 Jan;180(1):267-74 - PubMed
12. Lancet Neurol. 2011 Jun;10(6):520-9 - PubMed
13. Expert Rev Clin Pharmacol. 2012 May;5(3):245-56 - PubMed
14. Neurology. 2005 Mar 22;64(6):987-91 - PubMed
15. Expert Opin Investig Drugs. 2010 Dec;19(12):1603-12 - PubMed
16. Am J Pathol. 2012 Aug;181(2):642-51 - PubMed
17. Clin Neuropharmacol. 2011 Jan-Feb;34(1):28-35 - PubMed
18. N Engl J Med. 2012 Sep 20;367(12):1098-107 - PubMed
19. Expert Rev Neurother. 2005 Nov;5(6):721-7 - PubMed
20. Acta Neuropathol. 2012 Sep;124(3):411-24 - PubMed
21. Mult Scler. 2011 Nov;17(11):1341-50 - PubMed
22. Acta Neurol Scand. 2011 Aug;124(2):75-84 - PubMed
23. N Engl J Med. 2010 Feb 4;362(5):402-15 - PubMed
24. J Neuroimmunol. 2012 Oct 15;251(1-2):14-24 - PubMed
25. Mult Scler. 2010 Feb;16(2):197-207 - PubMed
26. N Engl J Med. 2010 Feb 4;362(5):416-26 - PubMed
27. Lancet. 1994 Jul 2;344(8914):9-13 - PubMed
28. Neurology. 2012 Jun 5;78(23):1877-85 - PubMed
29. N Engl J Med. 2006 Sep 14;355(11):1124-40 - PubMed
30. Brain. 2011 Mar;134(Pt 3):678-92 - PubMed
31. N Engl J Med. 2011 Oct 6;365(14):1293-303 - PubMed
32. N Engl J Med. 2012 Mar 15;366(11):1000-9 - PubMed
33. BMC Dev Biol. 2011 Jun 13;11:37 - PubMed
34. N Engl J Med. 2012 Sep 20;367(12):1087-97 - PubMed
35. N Engl J Med. 2010 Feb 4;362(5):387-401 - PubMed
36. Clin Immunol. 2012 Jan;142(1):49-56 - PubMed
37. Neurology. 2006 Mar 28;66(6):894-900 - PubMed
38. Lancet Neurol. 2011 Apr;10(4):329-37 - PubMed

Publication Types

• Journal Article